The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.622
Ask: 1.68
Change: 0.065 (4.10%)
Spread: 0.058 (3.576%)
Open: 1.648
High: 1.65
Low: 1.646
Prev. Close: 1.585
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: InfraStrata Targets Breakeven At Titanic Shipyard

Fri, 01st May 2020 11:18

(Alliance News) - The following is a round-up of quarterly, interim or full-year reports by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

InfraStrata PLC - natural gas storage and infrastructure - Pretax loss in six months to January 31 widens to GBP2.9 million from GBP394,627 amid sharp rise in management and administrative expenses to GBP2.8 million. Generates revenue of GBP515,230, versus none last year. Targets break-even at Harland & Wolff Belfast shipyard inside next 12 months.

----------

Flowtech Fluidpower PLC - fluid power components and services - Revenue in 2019 edges 0.3% higher to GBP112.4 million from GBP112.1 million, but pretax profit falls by 32% to GBP4.7 million from GBP6.9 million. Reports GBP1.7 million in depreciation of right-of-use assets, while administrative expenses rise 12% to GBP26.2 million. Decides against final dividend, means full-year payout down 65% to 2.13 pence per share from 6.07p.

----------

Block Energy PLC - exploration and production - Posts a widened pretax loss in 18 months to December 31. Previously changed its year-end date from June 30. Loss totalled USD6.1 million versus USD2.0 million. Generated revenue of USD314,000 versus USD179,000.

----------

Aminex PLC - oil & gas producer - Pretax loss in 2019 narrowed to USD15.2 million from USD48.5 million. Reported exploration impairments of USD10.9 million, down 75%. Revenue fell 42% to USD357,000 from USD617,000.

----------

Emmerson PLC - potash developer - Pretax loss in 2019 narrowed to GBP1.1 million from GBP1.8 million, amid absence of GBP698,000 in reverse acquisition expenses. Has moved to cut down on expenditure amid Covid-19.

----------

Taseko Mines Ltd - copper producer - Says revenue in three months to March 31 down 12% year-on-year to CAD62.1 million, about GBP35.2 million. Copper production up 30% to 32.4 million pounds from 24.9 million pounds.

----------

Panther Metals PLC - minerals explorer - Pretax loss in 2019 widened to GBP749,948 from GBP519,134 due to initial public offering costs of GBP305,134. Says outlook positive amid promising gold market.

----------

Shefa Gems Ltd - exploration and development - Swings to loss of NIS7.9 million, about GBP1.8 million, from NIS6.0 million. Aiming to continue mine planning procedures with the Israeli Lands Authority.

----------

Africa Opportunity Fund Ltd - investor - Net asset value per share at December 31 year-end down 4.9% to USD0.638 from USD0.671. Says performance lagged that of the Lusaka Stock Exchange in 2019.

----------

Marwyn Value Investors Ltd - investor - Reports share price total return of negative 17% compared to FTSE All-Share which gained 19%. Net assets down 29% to GBP105.0 million from GBP147.1 million.

----------

Papillon Holdings PLC - investment vehicle - Pretax loss in 2019 widens to GBP582,000 from GBP397,000. Administrative expenses up 20% to GBP443,000. Says acquisition of 50% stake in Pace Cloud Ltd progressing well.

----------

Golden Rock Global PLC - investment vehicle - Pretax loss in 2019 stretched to GBP393,871 from GBP227,983. Professional fees more than doubled to GBP272,308 during year where it came close to sealing acquisition before target company pulled out.

----------

New Century AIM VCT2 PLC - venture capital trust - 2019 NAV per share inches 2.4% higher to 49.53p from 48.38p, but axes dividend after 3.40p payout in 2018. Says UK general election result boosted certainty but notes volatility from Covid-19.

----------

Conygar Investment Co PLC - investor - Net asset value per share down 0.2% to 177.8 pence in six months to March 31 from 178.2p in September. NAV hurt by GBP1.3 million writedown at Cross Hands retail park in Carmarthenshire, Wales, due to Covid-19.

----------

Pires Investments PLC - investor - Net asset value in year ended October 31 climbs sharply to GBP2.6 million from GBP949,617 in year before. Pretax profit more than doubles to GBP865,510 from GBP322,069.

----------

Cardiff Property PLC - property investor - Ups dividend for six months to March 31 by 4.3% to 4.8 pence per share from 4.6p and NAV per share up 5.4% to 23.03p from 21.84p. Reports property market has uncertain picture due to Covid-19 but says Thames Valley area it operates in has been historically resilient.

----------

Weiss Korea Opportunity Fund Ltd - real estate investment - NAV per share rises 3.7% in 2019 to GBP1.5559 from GBP1.4993. Raises annual dividend by 21% to 4.1195p per share from 3.4155p. Noted that it outperformed the MSCI South Korea Index in 2019.

----------

Sigma Capital Group PLC - residential development - Revenue in 2019 rises 11% to GBP13.9 million from GBP12.5 million, with pretax profit climbing 17% to GBP13.0 million from GBP12.2 million. Holds total payout at 2.0p per share. Says Covid-19 impact difficult to predict. Will change year-end date to September 30 to better reflect season trading patterns.

----------

Highcroft Investments PLC - property investor - Net asset value per share falls 2.7% in 2019 to 1,175p from 1,205p. Slices final dividend by 20% to 27p per share from 33.75p, total payout down 8.6% to 48p from 52.50p. Net property income up 16% to GBP5.7 million and 12% rise in property valuation to GBP86.7 million from GBP77.7 million.

----------

Hemogenyx Pharmaceuticals PLC - cancer therapies - Pretax loss narrows to GBP1.5 million in 2019 from GBP1.6 million. Administrative expenses down 2.5% to GBP1.6 million and company reports other income of GBP213,126, more than double the amount from 2018.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 12:19

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.